Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
183 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anal Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 3, 5 and 2 respectively. Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anal Cancer - Overview 6 Anal Cancer - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Products under Development by Companies 10 Anal Cancer - Therapeutics Assessment 11 Assessment by Target 11 Assessment by Mechanism of Action 13 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Anal Cancer - Companies Involved in Therapeutics Development 19 Advaxis Inc 19 Amgen Inc 19 Atara Biotherapeutics Inc 20 Bayer AG 20 BeiGene Ltd 21 Cell Medica Ltd 21 Eli Lilly and Company 22 Immunovaccine Inc 22 ISA Pharmaceuticals BV 23 Merck & Co Inc 23 Millennium Pharmaceuticals Inc 24 Ono Pharmaceutical Co Ltd 24 Oryx GmbH & Co KG 25 PDS Biotechnology Corp 25 Sun Pharma Advanced Research Company Ltd 26 Taiwan Liposome Company Ltd 26 Anal Cancer - Drug Profiles 27 alisertib - Drug Profile 27 ATA-368 - Drug Profile 33 axalimogene filolisbac - Drug Profile 34 BAY-1125976 - Drug Profile 52 BGBA-317 - Drug Profile 53 cisplatin - Drug Profile 55 CMD-004 - Drug Profile 56 CUE-101 - Drug Profile 57 CUE-201 - Drug Profile 58 DPXE-7 - Drug Profile 59 ISA-101 - Drug Profile 60 nivolumab - Drug Profile 64 paclitaxel albumin free - Drug Profile 104 panitumumab - Drug Profile 105 PDS-0101 - Drug Profile 111 pembrolizumab - Drug Profile 113 prexasertib - Drug Profile 161 TLC-388 - Drug Profile 163 Vicoryx - Drug Profile 165 Anal Cancer - Dormant Projects 166 Anal Cancer - Discontinued Products 167 Anal Cancer - Product Development Milestones 168 Featured News & Press Releases 168 Appendix 180 Methodology 180 Coverage 180 Secondary Research 180 Primary Research 180 Expert Panel Validation 180 Contact Us 180 Disclaimer 181
List of Tables
Number of Products under Development for Anal Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Anal Cancer - Pipeline by Advaxis Inc, H1 2017 Anal Cancer - Pipeline by Amgen Inc, H1 2017 Anal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017 Anal Cancer - Pipeline by Bayer AG, H1 2017 Anal Cancer - Pipeline by BeiGene Ltd, H1 2017 Anal Cancer - Pipeline by Cell Medica Ltd, H1 2017 Anal Cancer - Pipeline by Eli Lilly and Company, H1 2017 Anal Cancer - Pipeline by Immunovaccine Inc, H1 2017 Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017 Anal Cancer - Pipeline by Merck & Co Inc, H1 2017 Anal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Anal Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017 Anal Cancer - Pipeline by PDS Biotechnology Corp, H1 2017 Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Anal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017 Anal Cancer - Dormant Projects, H1 2017 Anal Cancer - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.